Literature DB >> 12421140

Antithrombin deficiency: issues in laboratory diagnosis.

Kandice Kottke-Marchant1, Alexander Duncan.   

Abstract

OBJECTIVE: To review the current understanding of the pathophysiology of antithrombin deficiency and its role in congenital thrombophilia. Recommendations for diagnostic testing of antithrombin function and concentration, derived from the medical literature and consensus opinions of recognized experts in the field, are included. These recommendations specify whom, how, and when to test. DATA SOURCES: Review of the published medical literature. DATA EXTRACTION AND SYNTHESIS: A summary of the medical literature and proposed testing recommendations were prepared and presented at the College of American Pathologists Conference XXXVI: Diagnostic Issues in Thrombophilia. After discussion at the conference, consensus recommendations presented in this article were accepted after a two-thirds majority vote by the participants.
CONCLUSIONS: Antithrombin deficiency is an infrequent genetic abnormality that may be a significant contributing cause of thrombophilia. Antithrombin deficiency also may be observed in conjunction with other genetic or acquired risk factors. Assay of antithrombin plasma levels is appropriate in the laboratory evaluation of individuals with thrombophilia, preferably using a functional, amidolytic antithrombin assay. The diagnosis of antithrombin deficiency should be established only after other acquired causes of antithrombin deficiency, such as liver disease, consumptive coagulopathy, or heparin therapy, are excluded. A low antithrombin level should be confirmed with a subsequent assay on a fresh specimen, and family studies may be helpful to establish the diagnosis. Antigenic antithrombin assays may be of benefit in subclassification of the type of antithrombin deficiency and to confirm the decreased antithrombin level in patients with type I deficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421140     DOI: 10.5858/2002-126-1326-AD

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  18 in total

1.  Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.

Authors:  Yao-Hsu Yang; Kwan-Ki Hwang; John FitzGerald; Jennifer M Grossman; Mihaela Taylor; Bevra H Hahn; Pojen P Chen
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 2.  Clinical use and the Italian demand for antithrombin.

Authors:  Giancarlo M Liumbruno; Massimo Franchini; Monica Lanzoni; Fabio Candura; Stefania Vaglio; Samantha Profili; Liviana Catalano; Giuseppina Facco; Simonetta Pupella; Gabriele Calizzani; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

3.  Antithrombin deficiency in pregnancy.

Authors:  Shivani Durai; Lay Kok Tan; Serene Lim
Journal:  BMJ Case Rep       Date:  2016-05-20

4.  Frequent association of thrombophilia in cerebral venous sinus thrombosis.

Authors:  Makoto Ikejiri; Akihiro Shindo; Yuichiro Ii; Hidekazu Tomimoto; Norikazu Yamada; Takeshi Matsumoto; Yasunori Abe; Kaname Nakatani; Tsutomu Nobori; Hideo Wada
Journal:  Int J Hematol       Date:  2012-03       Impact factor: 2.490

Review 5.  [Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment].

Authors:  R Weber; E Busch
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

Review 6.  Antibodies to serine proteases in the antiphospholipid syndrome.

Authors:  Pojen P Chen; Ian Giles
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

7.  Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study.

Authors:  Benilde Cosmi; Cristina Legnani; Alberto Tosetto; Vittorio Pengo; Angelo Ghirarduzzi; Adriano Alatri; Domenico Prisco; Daniela Poli; Armando Tripodi; Gualtiero Palareti
Journal:  J Thromb Thrombolysis       Date:  2009-03-14       Impact factor: 2.300

8.  Relationship between assays of inflammation and coagulation: a novel interpretation of the canine activated clotting time.

Authors:  Teresa Cheng; Karol A Mathews; Anthony C G Abrams-Ogg; R Darren Wood
Journal:  Can J Vet Res       Date:  2009-04       Impact factor: 1.310

9.  Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients.

Authors:  Akihiro Shindo; Hideo Wada; Hidehiro Ishikawa; Ai Ito; Masaru Asahi; Yuichiro Ii; Makoto Ikejiri; Hidekazu Tomimoto
Journal:  Int J Hematol       Date:  2014-03-06       Impact factor: 2.490

Review 10.  Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options.

Authors:  Peter S Maclean; R Campbell Tait
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.